Natixis Advisors LLC Has $1.77 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Natixis Advisors LLC boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 8.3% in the third quarter, HoldingsChannel reports. The firm owned 153,717 shares of the company’s stock after acquiring an additional 11,726 shares during the period. Natixis Advisors LLC’s holdings in Roivant Sciences were worth $1,774,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Roivant Sciences in the 2nd quarter valued at approximately $34,000. US Bancorp DE grew its holdings in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares during the period. Point72 Hong Kong Ltd bought a new stake in shares of Roivant Sciences in the 2nd quarter valued at $36,000. Quarry LP acquired a new stake in Roivant Sciences during the 2nd quarter worth $53,000. Finally, Acadian Asset Management LLC acquired a new position in Roivant Sciences in the first quarter valued at about $72,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $12.46 on Tuesday. The firm has a 50-day moving average of $11.69 and a 200-day moving average of $11.33. The company has a market cap of $9.07 billion, a price-to-earnings ratio of 2.22 and a beta of 1.24. Roivant Sciences Ltd. has a one year low of $8.61 and a one year high of $13.06.

Insider Activity at Roivant Sciences

In other news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00. Following the sale, the chief operating officer now directly owns 606,525 shares of the company’s stock, valued at approximately $6,865,863. This represents a 14.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $11.89, for a total value of $2,972,500.00. Following the transaction, the chief accounting officer now owns 209,322 shares of the company’s stock, valued at $2,488,838.58. The trade was a 54.43 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,677,309 shares of company stock valued at $43,283,184. Insiders own 7.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ROIV shares. Bank of America lifted their price objective on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.